CliffBio
biologic

Darzalex

daratumumab

Loss of exclusivityNovember 2027projected — 12-year biologic exclusivity estimate
CompanyJanssen Biotech →View the full company profile on CliffBio

Drug detail

Brand nameDarzalex
Active ingredientdaratumumab
Strength400MG/20ML
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalNovember 2015
Marketing statusRx

More from Janssen Biotech

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Darzalex patent cliff — loss of exclusivity November 2027 | CliffBio